To determine the ideal parameters for both CD38- and CD138-targeted nanoparticle formulations, in vivo biodistribution studies of nanoparticles were analyzed using a subcutaneous xenograft mouse model of multiple myeloma. The gene discussed is SDC1; the disease is AL amyloidosis.